Could cause temporary or reversible harm; serious harm is unlikely.
CGMP Deviations: recalling drug products following an FDA inspection.
| Brand name | GLYCOPYRROLATE |
| Generic name | GLYCOPYRROLATE |
| Active ingredient(s) | GLYCOPYRROLATE |
| Distributed by / for | Accord Healthcare, Inc. Durham, NC 27703, USA |
| NDC | 16729-473-31 |
| Full product label | Glycopyrrolate Injection, USP 1 mg/5 mL (0.2 mg/mL) 5 mL Multiple Dose Vial, x 10 vials carton, Rx Only, Manufactured for: Accord Healthcare, Inc. Durham, NC 27703, USA. Manufactured by: Intas Pharmaceuticals Limited, Pharmez, Ahmedabad-382 213, INDIA 5mL vial NDC 16729-473-31 UPC 3 16729 47331 6; carton NDC 16729-473-03 UPC 3 16729 47303 3 |
| Recalling firm | Accord Healthcare, Inc. |
| Distribution | United States including Puerto Rico and Canada |
| Quantity | 3,164 vials |
| Recall initiated | 2023-02-07 |
| Report date | 2023-03-08 |
| Recall completed | 2024-04-22 |
| Recall number | D-0398-2023 |
| Classification | Class II |
| FDA status | Terminated |
| Origin on file | Durham NC United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗